They discovered that a vaccine adjuvant or “booster”, understood as C100, when injected straight into growths in an animal design, promotes powerful anti-tumor immunity.The scientists found that C100, derived from chitin– one of the most common building products in nature, and which provides strength to the exoskeletons of crustaceans, bugs, and the cell walls of fungi– is highly efficient at stimulating a key signaling and picking up molecule which manages anti-tumour immune responses.Their highly appealing work has been released today in the leading global journal Cell Reports Medicine.Ed Lavelle, Professor of Vaccine Immunology in Trinitys School of Biochemistry and Immunology and based in the Trinity Biomedical Sciences Institute, is the senior author of the research.”Mechanism and Potential of C100While further work is needed, the recently published study characterizes C100s mechanism of action and offers substantial hope that it may clear some of these obstacles and ignite the immune action researchers and clinicians are hoping for.The scientists now know how C100 specifically triggers one arm of a particular signaling pathway (cGAS-STING) without causing inflammatory reactions that could interfere with anti-tumour resistance and which might otherwise avoid therapies from achieving medical success.Additionally, the team found that injecting C100 led to synergistic restorative effects with a “checkpoint blocker”, which can release the brakes on the immune response.”Our work provides comprehensive new insights into how C100 works, which is crucial as you need a functional plan to be able to develop a therapeutic fight plan, and we now have significant hope that C100 can be developed into a highly efficient adjuvant for use in cancer immune treatments in the future.
